Proven Connect Logo
GlycoScoreDx Ltd
GlycoScore will drastically reduce over-diagnosis so that only men with a high risk of prostate cancer need to undergo biopsies. This will improve care for patients and also provide cost savings for health care systems. In addition, GlycoScore will also speed up diagnosis, identify aggressive cancers sooner and potentially save lives.
Investment Overview
Target: January 1, 1970
Minimum: £1m
Stage: MId study
Minimum: £1m

Share this

GlycoScore will drastically reduce over-diagnosis so that only men with a high risk of prostate cancer need to undergo biopsies. This will improve care for patients and also provide cost savings for health care systems. In addition, GlycoScore will also speed up diagnosis, identify aggressive cancers sooner and potentially save lives.

Investment Details

Unique panel of 3 aberrantly glycosylated proteins relevant to progression​

Glycosylation = carbohydrate-associated post-translational modifications = tumour cell signature​

Alterations in glycosylation directly impact cell growth and survival and modulate tumour-induced immunomodulation and eventual metastasis.​

PSA is a glycoprotein - elevated in non-cancerous conditions also (diagnostic grey zone 4-10ng = 25% chance of PC)​

Funding needed to conduct a 12 month study to determine whether the test is able to predict high vs low grade prostate cancer

  • Established 2018​
  • Newcastle spin-out​
  • Research phase funded by Prostate Cancer UK​
  • April 2021 £1m seed funding​
  • Forecasting cash positive within 5 years​
  • Level of investment est £1.5m
Investment Highlights
Established 2018
Research phase funded by Prostate Cancer UK
April 2021 £1m seed funding
Forecasting cash positive within 5 years
Level of investment est £1.5m